Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 5
Submit an article Journal homepage
91
Views
17
CrossRef citations to date
0
Altmetric
Review

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus

Graham R Foster Department of Adult and Paediatric Gastroenterology, The Royal London Hospital, Turner Street, London, E1 2AD, UK. [email protected]
Pages 685-691 | Published online: 02 Mar 2005

Bibliography

  • CHOO QL, KUO G, WEINER AJ et al: Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis clone. Science (1989) 244:359–361.
  • ZANETTI AR, TANZI E, PACCAGNINI S et al.: Mother to infant transmission of HCV. Lancet (1995) 345:273–279.
  • POYNARD T, BED OSSA E OPOLON P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet (1997) 349:825–832.
  • •A first rate study on a huge cohort of patients analysing the natural history of fibrosis progression in patients with CHC.
  • TONG MJ, EL-FARRA NS, REIKES AR, CO RL: Clinical outcomes after transfusion associated hepatitis C virus. N Engl. 1. Med. (1995) 332:1463–1466.
  • ALTER MJ, KRUSZON-MORAN D, NAINAN OV et al: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl. J. Med. (1999) 341(8):556–562.
  • ARMSTRONG GL, ALTER MJ, MCQUILLAN GM, MARGOLIS HS: The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 31(3):777–782.
  • •An intersting perspective on the probable future costs of caring for patients with chronic HCV.
  • ZOU S, TEPPER M, EL SAADANY S: Prediction of hepatitis C burden in Canada. Can. 1. Castroenteral (2000) 14(7):575–580.
  • Global surveillance and control of hepatitis C. Report of a WHO Consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. 1. Viral Hep. (1999) 6:35–47.
  • PRADAT P, TREPO C: HCV: epidemiology, modes of transmission and prevention of spread. Baillieres Best Pract. Res. CliI7. CaSITOellIETOL (2000) 14(2):201–210.
  • EASL International Consensus Conference on hepatitis C, Paris, France, 26–27 February, 1999. Consensus statement. I Hepatal (1999) 31\(Suppl. 1):3–8.
  • MALAGUARNERA M, RESTUCCIA S, TROVATO G et al: Interferon a treatment in patients with chronic hepatitis C. A meta-analytical evaluation.Chu. Drug Invest. (1995) 9:141–149.
  • POYNARD T, MARCELLIN P, LEE SS etal.: Randomised trial of interferon a2b Plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352(9138):1426–1432.
  • •A landmark trial evaluating the value of adding ribavirin to interferon treatment regimes for patients with CHC.
  • MCHUTCHISON JG, GORDON SC, SCHIFF ER et al: Interferon a2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl. 1. Med. (1998) 339(21):1485–1492.
  • •A landmark trial evaluating the value of adding ribavirin to interferon treatment regimes for patients with chronic HCV.
  • HULTGREN C, MILICH DR, WETLAND 0, SALLBERG M: The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Viral. (1998) 79(Pt 10):2381–2391.
  • FATTOVICH G, GIUSTINA G, FAVARATO S, RUOL A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with a-interferon. 1. Hepatal (1996) 24:38–47.
  • FOSTER GR: Hepatitis C virus infection: quality of life and side effects of treatment.I Hepatal (1999) 31\(Suppl. 0:250–254.
  • FOSTER GR, GOLDIN RD, MAIN J, MURRAY-LYON I, HARGREAVES S, THOMAS HC: Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. Br. Med. 1 (1997) 315 (7106):453–458.
  • FOSTER GR: Interferons in host defense. &min. Liver Dis. (1997) 17(4):287–295.
  • BAILON P, PALLERONI A,SCHAFFER CA et al.: Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon ciL for the treatment of hepatitis C. Bioconjug. Chem. (2001) 12 (2) : 195–202.
  • GLUE P, FANG JW, ROUZIER-PANIS R etal.: Pegylated interferon-a:pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Chu. Pharmacal Ther. (2000) 68(5):556–567.
  • MODI M: The pharmacokinetics behaviour of pegylated (40 kDa) interferon a2a (pegasys) in chronic hepatitis C patients after multiple dosing. Hepatology (2000).
  • ZEUZEM S, FEINMAN SV,RASENACK J et al: Peginterferon a2. in patients with chronic hepatitis C.N Engl. 1. Med. (2000) 343(23):1666–1672.
  • Ltd, SP, VIRAFERON PEC - Summary of product characteristics (2000).
  • REDDY KR, WRIGHT TL,POCKROS PJ et al.: Efficacy and safety of pegylated (40-kDa) interferon aa compared with interferon a2b in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 33(2):433–438.
  • HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG et al: Peginterferon a2a in patients with chronic hepatitis C and cirrhosis. N Engl. I Med. (2000) 343(23):1673–1680.
  • •An important study looking at the use of 40 ItE) PEG-IFNaza monotherapy in patients with HCV-related cirrhosis.
  • LINDSAY KL, TREPO C, HEINTGES T et al.: A randomized, double-blind trial comparing pegylated interferon a2b to interferon a2b as initial treatment for chronic hepatitis C. Hepatology (2001) 34(2)395–403.
  • MANNS M, MCHUTCHINSON J: Peginterferon a2b plus ribavirin compared to interferon a2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicentre, multinational Phase III randomized controlled trial, in AASLD, Dallas, USA (2000).
  • •An important clinical trial comparing the two PEG-IFNs plus ribavirin with standard IFN and ribavirin.
  • FRIED M, SHIFFMAN ML, REDDY R et al.: Pegylated (40 kDa) Interferon aL (pegasys) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study, in DDWAtlanta, USA (2001).
  • •An important clinical trial comparing the two PEG-IFNs plus ribavirin with standard IFN and ribavirin.
  • FRIED MW, SHIFFMAN ML, REDDY KR etal.: Peginterferon az„ plus ribavirin for chronic hepatitis C virus infection. N Engl. j. Med. (2002) 347(13): 975–982.
  • HADZIYANNIS S et al.: Peg-interferon az,(40kD) (pegasys) in combination with ribavirin: efficacy and safety results from a phase III randomised, double blind, multicentre study examining effect and duration of treatment and ribavirin dose.Hepatol. (2002) 36\(Suppl. 1):3.

Websites

  • http://www.nice.org.ukReport of the national institute for clinical excellence (2000). Guidance on the use of ribavirin and IFN-a for hepatitis C (2000).
  • http://consensus.nih.gov/cons/116/ 116cdc_intro.htm NIH consensus statement, management of hepatitis C (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.